Cargando…

Real-world Validation of TMB and Microsatellite Instability as Predictive Biomarkers of Immune Checkpoint Inhibitor Effectiveness in Advanced Gastroesophageal Cancer

Patients with advanced gastroesophageal cancer (mEG) and tumor mutational burden ≥10 mut/Mb (TMB ≥ 10) have more favorable outcomes on immune checkpoint inhibitor (ICPI) monotherapy compared with chemotherapy in subgroup analyses of randomized controlled trials. We sought to evaluate the robustness...

Descripción completa

Detalles Bibliográficos
Autores principales:	Graf, Ryon P., Fisher, Virginia, Creeden, James, Schrock, Alexa B., Ross, Jeffrey S., Nimeiri, Halla, Oxnard, Geoffrey R., Klempner, Samuel J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Association for Cancer Research 2022
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10010289/ https://www.ncbi.nlm.nih.gov/pubmed/36922935 http://dx.doi.org/10.1158/2767-9764.CRC-22-0161

Ejemplares similares

Durable responders in advanced NSCLC with elevated TMB and treated with 1L immune checkpoint inhibitor: a real-world outcomes analysis
por: Huang, Richard S P, et al.
Publicado: (2023)

ERBB2 Copy Number as a Quantitative Biomarker for Real-World Outcomes to Anti–Human Epidermal Growth Factor Receptor 2 Therapy in Advanced Gastroesophageal Adenocarcinoma
por: Zhang, Liangliang, et al.
Publicado: (2022)

Comparative Effectiveness of Immune Checkpoint Inhibitors vs Chemotherapy in Patients With Metastatic Colorectal Cancer With Measures of Microsatellite Instability, Mismatch Repair, or Tumor Mutational Burden
por: Quintanilha, Julia C. F., et al.
Publicado: (2023)

Comparative Effectiveness of Immune Checkpoint Inhibitors vs Chemotherapy by Tumor Mutational Burden in Metastatic Castration-Resistant Prostate Cancer
por: Graf, Ryon P., et al.
Publicado: (2022)

Tumor Mutational Burden in Real-World Patients With Pancreatic Cancer: Genomic Alterations and Predictive Value for Immune Checkpoint Inhibitor Effectiveness
por: Quintanilha, Julia C.F., et al.
Publicado: (2023)

Advances in immuno-oncology biomarkers for gastroesophageal cancer: Programmed death ligand 1, microsatellite instability, and beyond
por: Lin, Emily M, et al.
Publicado: (2018)

Pseudoprogression in microsatellite instability-high colorectal cancer during treatment with combination T cell mediated immunotherapy: a case report and literature review
por: Chae, Young Kwang, et al.
Publicado: (2017)

Real-world application of tumor mutational burden-high (TMB-high) and microsatellite instability (MSI) confirms their utility as immunotherapy biomarkers
por: Palmeri, M., et al.
Publicado: (2021)

NTRK fusion positive colorectal cancer is a unique subset of CRC with high TMB and microsatellite instability
por: Wang, Hui, et al.
Publicado: (2022)

BRAF V600E and RNF43 Co-mutations Predict Patient Outcomes with Targeted Therapies in Real-World Cases of Colorectal Cancer
por: Quintanilha, Julia C F, et al.
Publicado: (2023)

Biology and Targetability of the Extended Spectrum of PIK3CA Mutations Detected in Breast Carcinoma
por: Rugo, Hope S., et al.
Publicado: (2023)

Real-World Comprehensive Genomic Profiling Success Rates in Tissue and Liquid Prostate Carcinoma Specimens
por: Hiemenz, Matthew C, et al.
Publicado: (2022)

Clinical and pathological features associated with circulating tumor DNA content in real‐world patients with metastatic prostate cancer
por: Antonarakis, Emmanuel S., et al.
Publicado: (2022)

Tissue-Plasma TMB Comparison and Plasma TMB Monitoring in Patients With Metastatic Non-small Cell Lung Cancer Receiving Immune Checkpoint Inhibitors
por: Friedlaender, Alex, et al.
Publicado: (2020)

Evaluation of tissue- and plasma-derived tumor mutational burden (TMB) and genomic alterations of interest in CheckMate 848, a study of nivolumab combined with ipilimumab and nivolumab alone in patients with advanced or metastatic solid tumors with high TMB
por: He, Jie, et al.
Publicado: (2023)

Mismatch repair deficiency, next-generation sequencing-based microsatellite instability, and tumor mutational burden as predictive biomarkers for immune checkpoint inhibitor effectiveness in frontline treatment of advanced stage endometrial cancer
por: Hill, Breana L, et al.
Publicado: (2023)

The Prognostic Value of ctDNA and bTMB on Immune Checkpoint Inhibitors in Human Cancer
por: Wei, Jiayan, et al.
Publicado: (2021)

Biological Pathway-Derived TMB Robustly Predicts the Outcome of Immune Checkpoint Blockade Therapy
por: Miao, Ya-Ru, et al.
Publicado: (2022)

Microsatellite instability is a biomarker for immune checkpoint inhibitors in endometrial cancer
por: Yamashita, Hitomi, et al.
Publicado: (2017)

FGFR2‐Altered Gastroesophageal Adenocarcinomas Are an Uncommon Clinicopathologic Entity with a Distinct Genomic Landscape
por: Klempner, Samuel J., et al.
Publicado: (2019)

Editorial: Microsatellite and microsatellite instability
por: How-Kit, Alexandre, et al.
Publicado: (2023)

TMB in NSCLC: A Broken Dream?
por: Bravaccini, Sara, et al.
Publicado: (2021)

Comparison of PD-L1 tumor cell expression with 22C3, 28-8, and SP142 IHC assays across multiple tumor types
por: Maule, Jake G, et al.
Publicado: (2022)

Identifying Inconsistencies and Reporting Deficits in Therapeutic Massage and Bodywork (TMB) Case Reports Authored by TMB Practitioners: a TMB-Adapted CAse REport (CARE) Guidelines Audit Through 2014
por: Munk, Niki, et al.
Publicado: (2016)

Establishing guidelines to harmonize tumor mutational burden (TMB): in silico assessment of variation in TMB quantification across diagnostic platforms: phase I of the Friends of Cancer Research TMB Harmonization Project
por: Merino, Diana M, et al.
Publicado: (2020)

Genomic Biomarkers and Genome-Wide Loss-of-Heterozygosity Scores in Metastatic Prostate Cancer Following Progression on Androgen-Targeting Therapies
por: Zurita, Amado J., et al.
Publicado: (2022)

Plasma-based microsatellite instability detection strategy to guide immune checkpoint blockade treatment
por: Wang, Zhenghang, et al.
Publicado: (2020)

Inflammation promotes resistance to immune checkpoint inhibitors in high microsatellite instability colorectal cancer
por: Sui, Qiaoqi, et al.
Publicado: (2022)

Microsatellite Instability: A Review of Molecular Epidemiology and Implications for Immune Checkpoint Inhibitor Therapy
por: Kavun, Alexandra, et al.
Publicado: (2023)

Open the Technical Black Box of Tumor Mutational Burden (TMB): Factors Affecting Harmonization and Standardization of Panel-Based TMB
por: Sung, Meng-Ta, et al.
Publicado: (2022)

The Pan-Tumor Landscape of Targetable Kinase Fusions in Circulating Tumor DNA
por: Lee, Jessica K., et al.
Publicado: (2022)

PD-L1, TMB, MSI, and Other Predictors of Response to Immune Checkpoint Inhibitors in Biliary Tract Cancer
por: Rizzo, Alessandro, et al.
Publicado: (2021)

Progress and challenges in HER2-positive gastroesophageal adenocarcinoma
por: Zhao, Dan, et al.
Publicado: (2019)

Genomic Alterations of NTRK, POLE, ERBB2, and Microsatellite Instability Status in Chinese Patients with Colorectal Cancer
por: Guo, Yun, et al.
Publicado: (2020)

The vigorous immune microenvironment of microsatellite instable colon cancer is balanced by multiple counter-inhibitory checkpoints
por: Losa, Nicolas L, et al.
Publicado: (2015)

Microsatellite instability and immune checkpoint inhibitors: toward precision medicine against gastrointestinal and hepatobiliary cancers
por: Eso, Yuji, et al.
Publicado: (2019)

Immune Checkpoint Inhibition in Metastatic Colorectal Cancer Harboring Microsatellite Instability or Mismatch Repair Deficiency
por: Cohen, Romain, et al.
Publicado: (2021)

Microsatellite instability in ovarian neoplasms.
por: King, B. L., et al.
Publicado: (1995)

Microsatellite instability in colorectal cancer
por: Horvat, Matej, et al.
Publicado: (2011)

Microsatellite instability in colorectal cancer
por: Nojadeh, Jafar Nouri, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_v6cqnjj2fbc6vsiq4v56ul5o37